 | • レポートコード：B-MOR-08394 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、次世代シーケンシング（NGS）の世界市場について調べ、次世代シーケンシング（NGS）の世界規模、市場動向、市場環境、シーケンシングのタイプ別（全ゲノムシーケンシング、標的再シーケンシング、全エクソームシーケンシング、RNAシーケンシング、チップシーケンシング、De Novoシーケンシング、メチル化シーケンシング）分析、製品別（計測器、試薬・消耗品、サービス）分析、エンドユーザー別分析、用途別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・次世代シーケンシング（NGS）の世界市場インサイト ・次世代シーケンシング（NGS）の世界市場環境 ・次世代シーケンシング（NGS）の世界市場動向 ・次世代シーケンシング（NGS）の世界市場規模 ・次世代シーケンシング（NGS）の世界市場規模：シーケンシングのタイプ別（全ゲノムシーケンシング、標的再シーケンシング、全エクソームシーケンシング、RNAシーケンシング、チップシーケンシング、De Novoシーケンシング、メチル化シーケンシング） ・次世代シーケンシング（NGS）の世界市場規模：製品別（計測器、試薬・消耗品、サービス） ・次世代シーケンシング（NGS）の世界市場規模：エンドユーザー別 ・次世代シーケンシング（NGS）の世界市場規模：用途別 ・次世代シーケンシング（NGS）の世界市場：地域別市場規模・分析 ・次世代シーケンシング（NGS）の北米市場規模・予測 ・次世代シーケンシング（NGS）のアメリカ市場規模・予測 ・次世代シーケンシング（NGS）のヨーロッパ市場規模・予測 ・次世代シーケンシング（NGS）のアジア市場規模・予測 ・次世代シーケンシング（NGS）の日本市場規模・予測 ・次世代シーケンシング（NGS）の中国市場規模・予測 ・次世代シーケンシング（NGS）のインド市場規模・予測 ・次世代シーケンシング（NGS）の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global next generation sequencing market is expected to register a CAGR of 19.5% during 2018 to 2023 (the forecast period). The next generation sequencing is a DNA sequencing technology that has revolutionized genomic research, and has drawn huge attention from the scientific research community. North America dominates the market, owing to the increasing demand for advanced healthcare facilities, high investments for genomics and proteomics, and growing adoption of sequencing techniques in the region.
Rising Applications in Clinical Diagnosis
The increasing applications in clinical diagnosis is one the major factors responsible for the growth of this market. In the recent years, technologies, such as Illumina/Solexa, ABI/SOLiD, 454/Roche, and Helicos, have provided unique prospects for high-throughput functional genomic research. Its applications in the diagnosis includes a variety of illnesses, such as cancer, hematological disorders, neurology, psychiatry, dysmorphology, vision and hearing impairment, cardiology, and pharmacogenomics. Compared to Sanger sequencing, NGS has emerged as the dominant genomics technology because of its cost effectiveness and use in wide range of functional genomics applications, from sequencing a group of candidate genes, all coding regions (known as exome sequencing) to the entire human genome.
Other factors, such as the speed, cost and accuracy of NGS, efficient replacement for traditional technologies like microarrays, and rise in drug discovery applications demanding NGS technology, are also contributing to the growth of the next-generation sequencing market.
Legal and Ethical Issues
Ethical and legal discussions have always been part of medical research. Funding agencies and journals often submit genomic data from research participants to their databases – this allows investigators to control data. Giving such access, risks the identity of the individuals or families. The data and samples are sent from the databases without the consent of the participant, putting them at risk. The unidirectional flow of data out of the system creates a sense of exploitation and distrust. Therefore, the legal and ethical issues hinder the growth of the next-generation sequencing market.
Other factors hindering this market are lack of interpretation of complex data and lack of skilled professionals.
US to Dominate the Market Share
The United States is expected to dominate the NGS market globally during the forecast period. Due to the support of genomics research, various government bodies, like NHGRI (National Human Genome Research Institute, US), have supported the work on sequencing of the human genome and fund research on the genome’s structure, function, and role in health and disease. Further, The US National Human Genome Research Institute and the US National Academy of Medicine organized 90 leaders in genomic medicine from the United States and 25 other countries in Genomic Medicine Symposium in 2014, to identify opportunities for collaborations that promote the responsible practice of genomic medicine. Several government initiatives, developed healthcare infrastructure, and awareness among citizens are contributing to the growth of the market.
Key Developments in the Market
• February 2018 – HTG Molecular Diagnostics Inc., announced the issuance of Australian Patent for its technology for “Methods of Co-detecting mRNA and Small Non-coding RNA.”
• February 2018 – PacBridge Capital Partners (HK) Limited planned to fund Contextual Genomics Inc., a leading Canadian cancer genomics company to support its FIND IT assay.
• January 2018 – MedGenome expanded its NGS capabilities and forays into single-cell sequencing.
Major Players – AGILENT TECHNOLOGIES, DNASTAR INC., F. HOFFMANN-LA ROCHE LTD, GATC BIOTECH AG, ILLUMINA INC., MACROGEN INC., PACIFIC BIOSCIENCES OF CALIFORNIA INC., PERKINELMER INC., QIAGEN, AND THERMO FISHER SCIENTIFIC INC., amongst others.
Reasons to Purchase this Report
• Current and future of the global next-generation sequencing market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Applications in the Clinical Diagnosis
6.1.2 Speed, Cost, and Accuracy to Spur Market Growth
6.1.3 Efficient Replacement for Traditional Technologies (Microarrays)
6.1.4 Drug Discovery Applications Demanding NGS Technology
6.2 Market Restraints
6.2.1 Legal and Ethical Issues
6.2.2 Interpretation of Complex Data and Lack of Skilled Professionals
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type of Sequencing
7.1.1 Whole Genome Sequencing
7.1.2 Targeted Resequencing
7.1.3 Whole Exome Sequencing
7.1.4 RNA Sequencing
7.1.5 CHIP Sequencing
7.1.6 De Novo Sequencing
7.1.7 Methyl Sequencing
7.2 By Products
7.2.1 Instruments
7.2.2 Reagents & Consumables
7.2.3 Services
7.3 By End User
7.3.1 Hospitals
7.3.2 Academics
7.3.3 Biotech and Pharmaceutical Firms
7.4 By Application
7.4.1 Drug Discovery/Personalized Medicine
7.4.2 Genetic Screening
7.4.3 Diagnostics/Infectious Diseases
7.4.4 Agriculture and Animal Research
7.4.5 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 United States
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 Germany
7.5.2.3 United Kingdom
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 China
7.5.3.2 Japan
7.5.3.3 India
7.5.3.4 Australia
7.5.3.5 South Korea
7.5.3.6 Rest of Asia-Pacific
7.5.4 Middle East & Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of the Middle East & Africa
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Agilent Technologies
9.2 DNASTAR Inc.
9.3 F. Hoffmann-La Roche Ltd
9.4 GATC Biotech AG
9.5 Illumina Inc
9.6 Macrogen Inc.
9.7 Pacific Biosciences of California Inc.
9.8 PerkinElmer Inc.
9.9 Qiagen
9.10 Thermo Fisher Scientific Inc.
9.11 List Not Exhaustive
10. Future of the Market